Ann: Clinical milestones for 2024 & 2023 successes highlighted, page-13

Both are City of Hope sponsored with Mustang Biotech having in-licensed their technology from COH, as CHM has done. Based purely on current data available, the two technologies are line-ball.

Mustang's results are: 50% for DCR - 10.2 mths mdn survival - safety issues overcome via direct delivery into the brain

Chimeric's results are: 55% for DCR - 9.9 mths mdn survival - no safety issues

The above comparison doesn't take into account the fact that the CHM 1101 trial has yet to reach its maximal feasible dose and final patient cohort. Interestingly, CHM initiated a self-sponsored Phase 1B trial before Phase 1A trial completion - essentially to advance it in parallel with the first trial at a site in Texas. Perhaps interim data will be used towards our Ph2 regulatory package submission to the FDA.